for people ages 15-80 (full criteria)
at Davis, California and other locations
study started
estimated completion
Principal Investigator
by Chris Bowlus



This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.

Official Title

A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)


Primary Sclerosing Cholangitis Sclerosing Cholangitis Cholangitis, Sclerosing Sulfasalazine


You can join if…

Open to people ages 15-80

  1. Age 15-80
  2. A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC.
  3. ALP > 1.67 times the upper limit of normal (ULN) at screening
  4. Inflammatory bowel disease
  5. Subject must either be on a stable dose of ursodeoxycholic acid for > 6 months prior to screening or have been discontinued > 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 50% of all enrolled patients).

You CAN'T join if...

  1. Anticipated need for liver transplant within one year as determined by Mayo PSC risk score treatment
  2. Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy.
  3. Evidence of advanced liver disease including MELD score > 10, bilirubin > 3.0, platelet count < 100,000; or INR > 1.4
  4. Concomitant chronic liver disease including alcohol related liver disease, chronic hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary cholangitis
  5. Secondary causes of sclerosing cholangitis
  6. Known intolerance to sulfasalazine (including but not limited to allergy to sulfa or mesalamine) or folic acid
  7. History of cholangiocarcinoma or colon cancer within 5 years
  8. History of colectomy with > 1/3 bowel resected
  9. Treatment with any investigational agents, within two months or 5 half-lives of the investigational product, whichever is longer.
  10. . Active illicit drug or alcohol abuse
  11. . Current or past use of sulfasalazine within 6 months of enrollment.
  12. . Treatment with antibiotics within 3 months of start of medication
  13. . Need for chronic use of antibiotics
  14. . Evidence of bacterial cholangitis within 6 months of enrollment
  15. . In patients with Ulcerative Colitis, simple clinical colitis activity index of > 4 or, if Crohn's disease, a Harvey-Bradshaw index of > 5
  16. . Chronic kidney injury (eGFR < 59)
  17. . Pregnancy or lactation


  • University of California, Davis accepting new patients
    Davis California 95616 United States
  • University of Washington Medical Center accepting new patients
    Seattle Washington 98195 United States

Lead Scientist at UC Davis


accepting new patients
Start Date
Completion Date
Brigham and Women's Hospital
Sign up for this study
Phase 2
Study Type
Last Updated